ClinConnect ClinConnect Logo
Search / Trial NCT04422405

Functional Changes in the Stomach and Esophagus After One Anastomosis Gastric Bypass- OAGB

Launched by SPITAL LIMMATTAL SCHLIEREN · Jun 4, 2020

Trial Information

Current as of June 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how a specific weight-loss surgery called One Anastomosis Gastric Bypass (OAGB) affects the stomach and esophagus in people with obesity and related conditions. The researchers want to understand the changes that happen in these areas after the surgery, which could help improve treatment options for patients struggling with obesity and related issues like gastroesophageal reflux disease (GERD) and ulcers.

To be part of this study, participants need to be between 65 and 74 years old and have a body mass index (BMI) of over 35, meaning they are considered obese. They should have tried other methods to lose weight for at least two years without success and agree to participate in the study. However, some individuals cannot join, such as those with certain serious health conditions like cancer or Crohn's disease. If you decide to participate, you can expect to undergo evaluations related to your stomach and esophagus after the surgery, helping researchers gather valuable information to improve future treatments.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • BMI\> 35 kg/m2
  • 2 years of controlled conservative obesity treatment without weight reduction
  • patients should give their consent to participate in the study
  • Exclusion Criteria:
  • Less than 2 years of conservative obesity treatment
  • cancer
  • cirrhosis Child-Pough score A
  • Crohn's disease
  • serious psychiatric disorder, which led to in-hospital treatment in psychiatric clinic in the past two years
  • drug consumption
  • non-compliance
  • hiatal hernia \> 4cm
  • gastric pouch \< 10cm
  • Barett esophagus
  • erosive esophagitis Grade C or D according to the Los Angeles Classification
  • endoscopically proven gastric stricture
  • acid exposition time \> 6% (Lyon criteria)
  • reflux episodes\> 80 /24 hours (Lyon criteria)
  • insufficient low esophageal sphincter according to manometry findings
  • pathological findings in the impedance pH-metry (acid and non-acid reflux)

About Spital Limmattal Schlieren

Spital Limmattal Schlieren is a leading healthcare institution dedicated to delivering high-quality medical services and advancing clinical research. Located in Switzerland, the hospital specializes in a range of medical disciplines and is committed to improving patient outcomes through innovative treatments and therapies. As a clinical trial sponsor, Spital Limmattal Schlieren actively engages in research initiatives that aim to enhance medical knowledge and contribute to the development of new therapeutic options, ensuring adherence to rigorous ethical standards and regulatory requirements. With a focus on collaboration and excellence, the institution fosters an environment that supports scientific inquiry and promotes the health and well-being of the community it serves.

Locations

Schlieren, Zurich, Switzerland

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials